Well-being and stress vulnerability in ovarian cancer survivors during the COVID-19 pandemic

Rachel Telles; Sharaf Zia; Breanna Greteman; Premal Thaker; Frank Penedo; Mary Charlton; Michael Goodheart; Jessica Armer; Alyssa Noble; Anil Sood; Susan Lutgendorf

doi:10.1080/07347332.2023.2244474

Well-being and stress vulnerability in ovarian cancer survivors during the COVID-19 pandemic

Rachel Telles, Sharaf Zia, Breanna Greteman, Premal Thaker, Frank Penedo, Mary Charlton, Michael Goodheart, Jessica Armer, Alyssa Noble, Anil Sood, Susan Lutgendorf

Research output: Contribution to journal › Article › peer-review

Abstract

Objective: This study was designed to examine (1) whether ovarian cancer (OC) survivors would have greater well-being vs. elevated distress compared to community members during a universal health stressor (COVID-19) and (2) how resources and risk factors at diagnosis predicted vulnerability to a subsequent health-related stressor. Methods: One hundred seventeen OC survivors were recruited from two academic medical centers and compared to a community-based sample on COVID-related distress and disruption. Latent class analysis identified differentially impacted groups of survivors. Results: Survivors reported lower distress than community members. Predictors of higher distress included shorter-term survivorship, greater disruption, and poorer emotional well-being (EWB) at diagnosis. Survivors were divided into high- and low-COVID-19-impact subgroups; high-impact individuals endorsed higher perceived stress and lower EWB at diagnosis. Conclusion: Survivors reported lower COVID-related distress than community participants. While depression at diagnosis did not predict later distress, EWB was a strong predictor of response to a novel health-related stressor.

Original language	English
Journal	Journal of Psychosocial Oncology
DOIs	https://doi.org/10.1080/07347332.2023.2244474
State	Accepted/In press - 2023

Keywords

COVID-19
distress
ovarian cancer
stress
well-being

Access to Document

10.1080/07347332.2023.2244474

Cite this

@article{b8877ab1197e4e44baea5fe636d7138c,

title = "Well-being and stress vulnerability in ovarian cancer survivors during the COVID-19 pandemic",

abstract = "Objective: This study was designed to examine (1) whether ovarian cancer (OC) survivors would have greater well-being vs. elevated distress compared to community members during a universal health stressor (COVID-19) and (2) how resources and risk factors at diagnosis predicted vulnerability to a subsequent health-related stressor. Methods: One hundred seventeen OC survivors were recruited from two academic medical centers and compared to a community-based sample on COVID-related distress and disruption. Latent class analysis identified differentially impacted groups of survivors. Results: Survivors reported lower distress than community members. Predictors of higher distress included shorter-term survivorship, greater disruption, and poorer emotional well-being (EWB) at diagnosis. Survivors were divided into high- and low-COVID-19-impact subgroups; high-impact individuals endorsed higher perceived stress and lower EWB at diagnosis. Conclusion: Survivors reported lower COVID-related distress than community participants. While depression at diagnosis did not predict later distress, EWB was a strong predictor of response to a novel health-related stressor.",

keywords = "COVID-19, distress, ovarian cancer, stress, well-being",

author = "Rachel Telles and Sharaf Zia and Breanna Greteman and Premal Thaker and Frank Penedo and Mary Charlton and Michael Goodheart and Jessica Armer and Alyssa Noble and Anil Sood and Susan Lutgendorf",

note = "Funding Information: Dr. Thaker has done consulting for Merck, Astra Zeneca, Clovis, Glaxo Smith Kline, Eisai, Mersana, Seagen, Agenus, Novocure, Immunogen, Celsion, and Aadi Pharmaceuticals, has research funding from Merck and Glaxo Smith Kline, and is a Celsion shareholder; Dr. Sood has done consulting for Merck, Glaxo Smith Kline, ImmunoGen, Onxeo, and Kiyatec, is a Biopath shareholder, and has received royalties from Top Alliance. Publisher Copyright: {\textcopyright} 2023 Taylor & Francis Group, LLC.",

year = "2023",

doi = "10.1080/07347332.2023.2244474",

language = "English",

journal = "Journal of Psychosocial Oncology",

issn = "0734-7332",

}

TY - JOUR

T1 - Well-being and stress vulnerability in ovarian cancer survivors during the COVID-19 pandemic

AU - Telles, Rachel

AU - Zia, Sharaf

AU - Greteman, Breanna

AU - Thaker, Premal

AU - Penedo, Frank

AU - Charlton, Mary

AU - Goodheart, Michael

AU - Armer, Jessica

AU - Noble, Alyssa

AU - Sood, Anil

AU - Lutgendorf, Susan

N1 - Funding Information: Dr. Thaker has done consulting for Merck, Astra Zeneca, Clovis, Glaxo Smith Kline, Eisai, Mersana, Seagen, Agenus, Novocure, Immunogen, Celsion, and Aadi Pharmaceuticals, has research funding from Merck and Glaxo Smith Kline, and is a Celsion shareholder; Dr. Sood has done consulting for Merck, Glaxo Smith Kline, ImmunoGen, Onxeo, and Kiyatec, is a Biopath shareholder, and has received royalties from Top Alliance. Publisher Copyright: © 2023 Taylor & Francis Group, LLC.

PY - 2023

Y1 - 2023

N2 - Objective: This study was designed to examine (1) whether ovarian cancer (OC) survivors would have greater well-being vs. elevated distress compared to community members during a universal health stressor (COVID-19) and (2) how resources and risk factors at diagnosis predicted vulnerability to a subsequent health-related stressor. Methods: One hundred seventeen OC survivors were recruited from two academic medical centers and compared to a community-based sample on COVID-related distress and disruption. Latent class analysis identified differentially impacted groups of survivors. Results: Survivors reported lower distress than community members. Predictors of higher distress included shorter-term survivorship, greater disruption, and poorer emotional well-being (EWB) at diagnosis. Survivors were divided into high- and low-COVID-19-impact subgroups; high-impact individuals endorsed higher perceived stress and lower EWB at diagnosis. Conclusion: Survivors reported lower COVID-related distress than community participants. While depression at diagnosis did not predict later distress, EWB was a strong predictor of response to a novel health-related stressor.

AB - Objective: This study was designed to examine (1) whether ovarian cancer (OC) survivors would have greater well-being vs. elevated distress compared to community members during a universal health stressor (COVID-19) and (2) how resources and risk factors at diagnosis predicted vulnerability to a subsequent health-related stressor. Methods: One hundred seventeen OC survivors were recruited from two academic medical centers and compared to a community-based sample on COVID-related distress and disruption. Latent class analysis identified differentially impacted groups of survivors. Results: Survivors reported lower distress than community members. Predictors of higher distress included shorter-term survivorship, greater disruption, and poorer emotional well-being (EWB) at diagnosis. Survivors were divided into high- and low-COVID-19-impact subgroups; high-impact individuals endorsed higher perceived stress and lower EWB at diagnosis. Conclusion: Survivors reported lower COVID-related distress than community participants. While depression at diagnosis did not predict later distress, EWB was a strong predictor of response to a novel health-related stressor.

KW - COVID-19

KW - distress

KW - ovarian cancer

KW - stress

KW - well-being

UR - http://www.scopus.com/inward/record.url?scp=85168081461&partnerID=8YFLogxK

U2 - 10.1080/07347332.2023.2244474

DO - 10.1080/07347332.2023.2244474

M3 - Article

C2 - 37587850

AN - SCOPUS:85168081461

SN - 0734-7332

JO - Journal of Psychosocial Oncology

JF - Journal of Psychosocial Oncology

ER -

Well-being and stress vulnerability in ovarian cancer survivors during the COVID-19 pandemic

Abstract

Keywords

Access to Document

Other files and links

Fingerprint

Cite this